HER2 overexpression was more commonly observed in patients with lymph node metastasis (N0 disease, 13.2%; N1 disease, 13.3%; N2 disease, 30.3%; N3 disease, 35.1%; P = 0.003). This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.